PDPRA's Operational Challenges
Whether or not the new Prescription Drug Pricing Reduction Act is a good policy, if it is enacted, its proposals have to work as intended and ensure compliant operationalization, writes Jeremy Docken.
Non-compliance Costs Hundreds of Millions in Revenue
A look at the systemic problems resulting from the overlap of MDRP and 340B.
2 Commerce Drive Cranbury, NJ 08512